HyperLab Blog - Drug Discovery

This article highlights two case studies showing how the AI drug discovery platform HyperLab effectively identified lead compounds and optimized drug candidates in real-world research.

In January 2025, the U.S. Food and Drug Administration (FDA) approved several new drugs targeting various diseases.

We introduce a case study on utilizing Hyper Screening to develop a MARK4 inhibitor drug. This article covers the process from identifying initial hit compounds to analyzing experimental results.

AI Drug Discovery: From 5 Years to Just 3 Months—Discovering a 100nM Active Compound with Hyper Lab

Oncology, immunology, and metabolic diseases dominated the top 50 FDA-approved drugs in 2024, with innovative treatments like Lazertinib and diverse drug types.

Cobenfy is an FDA-approved oral schizophrenia treatment targeting muscarinic rather than dopamine receptors. Its rapid symptom improvement and fewer side effects hint at a paradigm shift, making upcoming clinical findings highly anticipated.

Seladelpar, a treatment for Primary Biliary Cholangitis, has received FDA accelerated approval. This rare autoimmune disease, mainly affecting middle-aged women, is now addressed by seladelpar’s high selectivity and fewer side effects.

In this article, we analyze the posters submitted to DDC 2024, categorized by country, organization, and topic.

We've summarized three important papers for AI drug discovery. These papers will help you understand the fundamentals of AI drug discovery and move forward with the latest research.

We've covered things to consider when defining a binding site during structure-based drug discovery research (SBDD).